Palliative Radiotherapy and Hormonal Deprivation for Prostate Cancer Induced Urinary Obstruction at a Sub-Saharan Tertiary Hospital

Palliative Radiotherapy and Hormonal Deprivation for Prostate Cancer Induced Urinary Obstruction at a Sub-Saharan Tertiary Hospital

November 22, 2016 at 8:19 AM 0 comments

*Sam Kaggwa,1 Israel Luutu,2 Moses Galukande1 1. Department of Surgery, College of Health Sciences, Makerere University, Kampala, Uganda 2. Department of Radiotherapy, Mulago National Referral Hospital, Kampala, Uganda *Correspondence to sam.kaggwa@gmail.com Disclosure: The authors have declared no conflicts of interest. Received: 23.10.15 Accepted: 20.04.16 Citation: EMJ Oncol. 2016;4[1]:130-133. Abstract TheRead More

How I Treat: Lung Cancer

How I Treat: Lung Cancer

April 5, 2016 at 8:59 AM 0 comments

*Antonio Rossi Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy *Correspondence to arossi_it@yahoo.it

Regorafenib in Advanced and Refractory Gastrointestinal Cancers

Regorafenib in Advanced and Refractory Gastrointestinal Cancers

April 5, 2016 at 8:57 AM 0 comments

*Ewen D. Legg Halcyon Medical Writing LTD., Thurso, UK *Correspondence to ewen.d.legg@gmail.com Disclosure: Medical writing assistance was funded by Bayer. Received: 08.02.16 Accepted: 09.03.16 Citation: EMJ. 2016;1[2]:18-25. Abstract The American Society of Clinical Oncology’s 2016 Gastrointestinal Cancer Symposium (ASCO-GI), held in San Francisco, California, USA, provided a forum for leadingRead More

Primary Paraganglioma of the Thyroid Gland: Clinical and Immunohistological Analysis with a Literature Review

Primary Paraganglioma of the Thyroid Gland: Clinical and Immunohistological Analysis with a Literature Review

April 5, 2016 at 8:46 AM 0 comments

*Julien Feghaly,1 George Astras,2 Marios Loizou,3 Giannis Panayiotou,3 Ariana Mooradian1 1. St. George’s University of London (Cyprus), Nicosia, Cyprus 2. Oncology Department, American Medical Center, Nicosia, Cyprus 3. General Surgery Department, Nicosia General Hospital, Nicosia, Cyprus *Correspondence to feghaly.julien@gmail.com Disclosure: The authors have declared no conflicts of interest. Received: 14.12.2015Read More

Utility of Exosomes in the Diagnosis and Treatment of Pancreatic Adenocarcinoma

Utility of Exosomes in the Diagnosis and Treatment of Pancreatic Adenocarcinoma

January 26, 2016 at 9:02 AM 0 comments

Leo I. Amodu, Asaph Levy, Crystal Kyaw, Darshan Padmanabhan, Alexandra Osman, Mukesh Tiwari, Jeffrey Nicastro, Gene Coppa, Ernesto Molmenti, *Horacio L. Rodriguez Rilo Center for Diseases of the Pancreas, Department of General Surgery, Hofstra North Shore-Long Island Jewish School of Medicine, Hempstead, New York, USA *Correspondence to Hrilo@nshs.edu Disclosure: TheRead More

Intelligent Application of Breast Cancer Trials Data in the Clinic

Intelligent Application of Breast Cancer Trials Data in the Clinic

November 12, 2015 at 9:08 AM 0 comments

Summary of presentations from the prIME Oncology satellite symposium held at the European Cancer Congress 2015 in Vienna, Austria, on 25th September 2015 Author: Joanne Franklin1 Chairperson: Sunil Verma2 Speakers: Sibylle Loibl,3 Pierfranco Conte,4 Peter Schmid,5 Christos Sotiriou6 1. prIME Oncology, The Hague, Netherlands 2. Sunnybrook Health Sciences Center, Toronto,Read More

Incorporating PARP Inhibition in Cancer Therapy: Key Questions, Expert Answers

Incorporating PARP Inhibition in Cancer Therapy: Key Questions, Expert Answers

November 12, 2015 at 9:08 AM 0 comments

Summary of presentations from the prIME Oncology satellite symposium held at the European Cancer Congress 2015 in Vienna, Austria, on 27th September 2015 Author: Tristin Abair1 Chairperson: Hilary Calvert2 Speakers: Nicoletta Colombo,3 Eric Pujade-Lauraine,4 Andrew Tutt,5 Eric Van Cutsem6 1. prIME Oncology, Atlanta, Georgia, USA 2. University College London, London,Read More

Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma: Results of a Randomised Phase III Trial (METEOR)

Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma: Results of a Randomised Phase III Trial (METEOR)

November 12, 2015 at 9:07 AM 0 comments

This late-breaking abstract was presented on 26th September 2015 in Presidential Session I, as part of the European Cancer Congress 2015 in Vienna, Austria Speaker: Toni Choueiri Dana–Farber Cancer Institute, Boston, Massachusetts, USA Disclosure: Toni Choueiri has received advisory board and consultation fees from Pfizer, GSK, Novartis, Merck, Bayer, andRead More

Current and Future Developments in the Treatment of CD30+ Lymphomas

Current and Future Developments in the Treatment of CD30+ Lymphomas

November 12, 2015 at 9:06 AM 0 comments

*Lena Specht,1 Christian Gisselbrecht2 1. Departments of Oncology and Haematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark 2. Institut d’Hématologie, Hôpital Saint-Louis, Paris, France *Correspondence to Lena.Specht@regionh.dk Disclosure: Lena Specht is a member of the advisory board for Takeda Pharmaceuticals. Support: The publication of this article was funded by Takeda. TheRead More

Re: State-Of-The-Art Treatment in Castration-Resistant Prostate Cancer – Forward to the past – Again

Re: State-Of-The-Art Treatment in Castration-Resistant Prostate Cancer – Forward to the past – Again

May 7, 2015 at 9:23 AM 0 comments

*Hannah C.P. Wilson, S. Imran A. Shah, Patricia Price, Paul D. Abel Department of Surgery and Cancer, Imperial College London, B-Block Hammersmith Campus, London, UK *Correspondence to hannah.wilson12@imperial.ac.uk Letter in response to: Castro E. et al. State-of-the-art treatment in castration-resistant prostate cancer. EMJ Oncol. 2014;2:100-5. Castro E. et al. choseRead More